Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America

Analyst Geoff Meacham upgraded Gilead to buy from neutral. He increased his target price for the stock by $7 to $95.

Partner with bartday.com. Kindly head here.

From our partners:

CITI.IO :: Business. Institutions. Society. Global Political Economy.

CYBERPOGO.COM :: For the Arts, Sciences, and Technology.

DADAHACKS.COM :: Parenting For The Rest Of Us.

ZEDISTA.COM :: Entertainment. Sports. Culture. Escape.

TAKUMAKU.COM :: For The Hearth And Home.

ASTER.CLOUD :: From The Cloud And Beyond.

LIWAIWAI.COM :: Intelligence, Inside and Outside.

GLOBALCLOUDPLATFORMS.COM :: For The World's Computing Needs.

FIREGULAMAN.COM :: For The Fire In The Belly Of The Coder.

ASTERCASTER.COM :: Supra Astra. Beyond The Stars.

BARTDAY.COM :: Prosperity For Everyone.

Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America

From our partners:

Top 10: Smart Cities

Tech Predictions For 2025 And Beyond

12 Days until Christmas: 8 Perfect Holiday Gift Ideas

IBM Study: Vehicles Believed to be Software Defined and AI Powered by 2035

Top 10: Smart Cities

Tech Predictions For 2025 And Beyond

12 Days until Christmas: 8 Perfect Holiday Gift Ideas

IBM Study: Vehicles Believed to be Software Defined and AI Powered by 2035

Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America

From our partners:

You May Also Like